MedTrace Logo

Enhanced Palliative Care in MDS and AML

NCT04226768 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-10-04

No results posted yet for this study

Summary

Objectives:

The purpose of this study is to evaluate the impact of enhanced haematology palliative care services to the most symptomatic group of blood cancer patients, namely myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).

Hypothesis to be tested:

To test whether early integration of dedicated palliative care will improve the quality of life, mood and caregiver burden in patients with MDS and AML.

Design and subjects:

This is a 24-month open-label randomized controlled trial. Subjects include patients with MDS and AML.

Study instruments:

Interventions will be carried out by a dedicated team comprising palliative care physicians, haematologists, palliative care nurse specialists, and social workers. Outcome measures will be determined using validated questionnaires and data collection tools.

Interventions:

In this trial, enhanced haematology palliative care integrated to conventional supportive care versus conventional supportive care alone will be compared.

Main outcome measures:

The primary outcome measures include quality of life, mood and caregiver burden. The secondary outcome measures include number of admissions to acute hospital and intensive care and overall survival.

Conditions

Interventions

OTHER

Enhanced Haematology Palliative Care ("Fast-track") Group

Early and proactive multidisciplinary care

OTHER

Conventional Care

Conventional care and referral as indicated

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Harinder Singh Harry Gill, MD · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-09
Primary Completion
2023-12-30
Completion
2023-12-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04226768 on ClinicalTrials.gov